Literature DB >> 17934092

Thoughts on health economics in rheumatoid arthritis.

Gisela Kobelt1.   

Abstract

In this manuscript we discuss the reasons why and how health economics is important, the type of economic studies that are relevant in healthcare to different stakeholders in general, and what analyses can and have been performed in the field of rheumatoid arthritis (RA). We will thus specifically address costs and outcome measurements in RA, as well as the need for modelling in chronic progressive diseases.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17934092      PMCID： PMC2095296          DOI： 10.1136/ard.2007.078964

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  22 in total

1.  Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference?

Authors:  M F Drummond; M Barbieri; J B Wong
Journal:  Med Decis Making       Date:  2005 Sep-Oct       Impact factor: 2.583

2.  Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis.

Authors:  John B Wong; Gurkirpal Singh; Arthur Kavanaugh
Journal:  Am J Med       Date:  2002-10-01       Impact factor: 4.965

3.  Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.

Authors:  Andreas Maetzel; Peter Tugwell; Maarten Boers; Francis Guillemin; Doug Coyle; Mike Drummond; John B Wong; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2003-04       Impact factor: 4.666

4.  Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'.

Authors:  J L Hülsemann; J Ruof; H Zeidler; T Mittendorf
Journal:  Rheumatol Int       Date:  2005-11-01       Impact factor: 2.631

5.  The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.

Authors:  G Kobelt; L Jönsson; A Young; K Eberhardt
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

6.  TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.

Authors:  G Kobelt; K Eberhardt; P Geborek
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

7.  Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

Authors:  A Brennan; N Bansback; A Reynolds; P Conway
Journal:  Rheumatology (Oxford)       Date:  2003-07-30       Impact factor: 7.580

8.  Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.

Authors:  A Brennan; N Bansback; R Nixon; J Madan; M Harrison; K Watson; D Symmons
Journal:  Rheumatology (Oxford)       Date:  2007-06-11       Impact factor: 7.580

9.  Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.

Authors:  Gisela Kobelt; Linus Jönsson; Peter Lindgren; Adam Young; Kerstin Eberhardt
Journal:  Arthritis Rheum       Date:  2002-09

Review 10.  Health economic issues in rheumatoid arthritis.

Authors:  G Kobelt
Journal:  Scand J Rheumatol       Date:  2006 Nov-Dec       Impact factor: 3.641
View more
  6 in total

1.  Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries.

Authors:  Kalle Mattila; Frank Buttgereit; Risto Tuominen
Journal:  Rheumatol Int       Date:  2015-05-26       Impact factor: 2.631

2.  Cost-effectiveness of biological therapy compared with methotrexate in the treatment for rheumatoid arthritis in Colombia.

Authors:  Carolina Valle-Mercado; Maria-Fernanda Cubides; Monica Parra-Torrado; Diego Rosselli
Journal:  Rheumatol Int       Date:  2013-08-02       Impact factor: 2.631

3.  Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis.

Authors:  András Inotai; Bernadette Rojkovich; Angéla Fülöp; Emese Jászay; Tamás Agh; Agnes Mészáros
Journal:  Rheumatol Int       Date:  2011-01-18       Impact factor: 2.631

4.  Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective.

Authors:  Márta Péntek; Bernadette Rojkovich; László Czirják; Pál Géher; Péter Keszthelyi; Attila Kovács; László Kovács; Zita Szabó; Zoltán Szekanecz; László Tamási; Ágnes Edit Tóth; Ilona Ujfalussy; Noémi Vártokné Hevér; Bálint Strbák; Petra Baji; Valentin Brodszky; László Gulácsi
Journal:  Eur J Health Econ       Date:  2014-05-16

5.  Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain.

Authors:  Ariel Beresniak; Rafael Ariza-Ariza; Jose Francisco Garcia-Llorente; Antonio Ramirez-Arellano; Danielle Dupont
Journal:  Int J Inflam       Date:  2011-06-28

6.  Impact of morning stiffness on working behaviour and performance in people with rheumatoid arthritis.

Authors:  Kalle Mattila; Frank Buttgereit; Risto Tuominen
Journal:  Rheumatol Int       Date:  2014-05-29       Impact factor: 2.631
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.